Wordt geladen...
Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going
• Azithromycin (AZM) is a promising drug candidate for the treatment of the COVID-19. • Studies so far on the use of AZM in COVID-19 patients have various methodological limitations. • The evidence on the efficacy of AZM as an adjunct to hydroxychloroquine for COVID-19 is not enough yet. • Combinati...
Bewaard in:
| Gepubliceerd in: | J Glob Antimicrob Resist |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7328586/ https://ncbi.nlm.nih.gov/pubmed/32622008 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jgar.2020.06.016 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|